BZD9L1 benzimidazole analogue hampers colorectal tumor progression by impeding angiogenesis

Figure 1 Cell viability and adhesion analyses of Ea. HY926 endothelial cells treated with different concentrations of BZD9L1. A: Cell viability was determined using the MTT assay. The inhibitory concentration of BZD9L1 in Ea HY926 is 5.20 μm ± 0.38 μm (n = 3) at 72 h; B: Real-time xCELLigence impedance analysis of the area under the curve of BZD9L1-treated Ea.HY926 cells in suspension over 5 h. BZD9L1 at 10 μM reduced the ability of the endothelial cells to adhere to the microtiter plates (E-Plates^®); C: Real-time xCELLigence impedance analysis of normalized cell index of BZD9L1-treated Ea.HY926 cells over 72 h. BZD9L1 at 2.5 μM and 5.0 μM had no significant impact on cell proliferation at 24 h and 48 h. Statistical analysis (^aP < 0.05; ^bP < 0.01), one-way ANOVA with Bonferroni posthoc test, n = 3 independent experiments using GraphPad Prism 9.4.0. Error bars represent SEM. VC: Vehicle control.